Scientific article
Open access

Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism

Published inEuropean heart journal, vol. 35, no. 28, p. 1836-1843
Publication date2014

Direct oral anticoagulants (DOACs) specifically target factor IIa or Xa and represent a major step forward in the treatment of acute- and long-term prevention of venous thrombo-embolism (VTE). They are at least as effective and as safe as conventional therapy (heparins and vitamin-K inhibitors) and have practical advantages, such as fixed dosing and no need for laboratory monitoring. These antithrombotic agents introduce a new paradigm for the day-to-day management of VTE. Direct oral anticoagulants should streamline the management of most patients with VTE and will facilitate care in the outpatient setting. Nevertheless, it remains uncertain how to select specific DOACs for particular profiles of patients, and the optimal management of bleeding complications is evolving.

Citation (ISO format)
FONTANA, Pierre, GOLDHABER, Samuel Z, BOUNAMEAUX, Henri. Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. In: European heart journal, 2014, vol. 35, n° 28, p. 1836–1843. doi: 10.1093/eurheartj/ehu027
Main files (1)
Article (Published version)
ISSN of the journal0195-668X

Technical informations

Creation02/28/2014 1:29:00 PM
First validation02/28/2014 1:29:00 PM
Update time03/14/2023 9:01:38 PM
Status update03/14/2023 9:01:38 PM
Last indexation01/16/2024 9:24:59 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack